IDH1/IDH2 Inhibition in Acute Myeloid Leukemia

IDH1/IDH2 Inhibition in Acute Myeloid Leukemia

Recently, the discovery of biological and clinical properties of mutated isoforms 1 and 2 mutations of isocitrate dehydrogenases (IDH) 1 and 2, affecting approximately 20% of patients with acute myeloid leukemia (AML), lead to the development of an individualized treatment strategy. Promoting differ...

Full description

Bibliographic Details
Main Authors: Claudio Cerchione, Alessandra Romano, Naval Daver, Courtney DiNardo, Elias Joseph Jabbour, Marina Konopleva, Farhad Ravandi-Kashani, Tapan Kadia, Maria Paola Martelli, Alessandro Isidori, Giovanni Martinelli, Hagop Kantarjian
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-03-01
Series:Frontiers in Oncology
Subjects:
acute myeloid leukemia
AML
enasidenib
IDH
isocitrate dehydrogenase
ivosidenib
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.639387/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.639387/full

Similar Items